NAD+ IV Therapy in Thailand: What's Actually Happening

NAD+ IV drips have become a fixture of wellness menus across Thailand's fast-growing medical tourism sector, marketed as a shortcut to cellular energy, recovery, and anti-aging. This article separates what is actually regulated from what is simply offered, and what the clinical evidence supports from what is marketing language — covering Thailand's general framework for licensing IV-administering clinics, the thin state of human evidence for NAD+ infusions specifically, and real safety actions regulators have taken against compounded NAD+ products, without naming or evaluating any individual provider.

The Regulatory Picture

There is no evidence that Thailand's FDA, Ministry of Public Health (MOPH), or Medical Council of Thailand has issued a specific approval, registration, or formal classification for NAD+ as an intravenous anti-aging therapy. That is not unique to Thailand — no major regulator anywhere, including the U.S. FDA, has approved an NAD+ IV product for anti-aging or longevity use. What does exist in Thailand is a general licensing framework that any facility offering IV services has to operate within: clinics must be licensed as medical facilities through provincial public health offices under the MOPH, medicines and injectable products used in them are supposed to be registered with the Thai FDA, and the people administering injections are expected to be licensed physicians or nurses under Medical Council and Nursing Council oversight.

Enforcement of that framework is visible in the news record. In February 2026, a Chonburi raid on an unlicensed Si Racha clinic — which had been advertising "vitamin drip" and cosmetic services on social media — resulted in four arrests and the seizure of unregistered medicines and unregistered weight-loss drugs; local public health officials confirmed the facility had never been licensed at all. Cases like this illustrate the real enforcement mechanism in Thailand: it targets unlicensed facilities and unregistered drug products generally, rather than NAD+ specifically, which does not appear to have its own distinct regulatory category in Thailand any more than it does elsewhere.

What NAD+ IV Therapy Actually Is

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme every cell uses for energy metabolism and DNA repair. The legitimate, long-established clinical touchpoint here is narrower than the marketing suggests: niacin and niacinamide, the vitamin B3 precursors the body uses to make NAD+, have recognized uses for B3 deficiency (pellagra) and, for niacin specifically, cholesterol management. The NAD+ molecule itself, delivered directly by IV, is not an approved drug product anywhere, and clinics offering it are using compounded preparations rather than an FDA- or Thai FDA-sanctioned medicine.

Historically, IV NAD+ was also promoted in addiction and detox clinics as a way to ease withdrawal — a use that journalists and researchers have reported lacks rigorous supporting trials. Today the same infusions are marketed more broadly for energy, "cellular repair," hangover recovery, and anti-aging — claims that go well beyond what the underlying biology has been shown to do in humans.

What the Evidence Shows — and Doesn't

The evidence base here deserves honest framing: it's genuinely early, and the gap between animal data and human data is wide.

• Animal studies are promising. Rodent research shows NAD+ precursors improving mitochondrial function and metabolic markers — enough to justify real scientific interest.
• Human oral-precursor trials are mixed and small. Trials of nicotinamide riboside (NR) and NMN have shown some benefit in limited populations (e.g., prediabetes, Parkinson's disease, peripheral artery disease), but other metabolic-health trials failed to replicate animal findings.
• IV-specific human evidence is essentially absent. A February 2026 systematic review covering 113 studies found no eligible controlled human trials of IV, intramuscular, or subcutaneous NAD+ for anti-aging or wellness purposes — the parenteral evidence base, the review's authors concluded, is currently absent.
• There's a basic biology problem. NAD+ is a large molecule that doesn't easily cross into cells and breaks down rapidly once outside them; a small 2019 pilot study found NAD+ cleared from plasma quickly, consistent with that breakdown.
• The "NAD+ declines with age" premise is itself being questioned. A 2026 study of whole blood NAD+ across multiple cohorts found no consistent decline with age or lifestyle factors, which — if confirmed — would undercut part of the rationale for supplementing it in the first place.

In short: credible researchers describe NAD+ biology as a genuinely interesting hypothesis worth continued study, while being clear that IV infusions specifically have almost no published, well-controlled human data behind the anti-aging claims attached to them.

Thailand's Wellness Tourism Context

Whatever the evidence gaps around any single infusion, Thailand's broader wellness and medical tourism sector is real, large, and growing with government backing. Thailand's Ministry of Tourism and Sports counted over 92,800 wellness-related businesses generating an estimated 670 billion baht (roughly $20.7 billion) in 2025, with the Global Wellness Institute reporting that Thai wellness tourism grew more than 120% off its pandemic lows. Thailand's Ministry of Public Health has also outlined a "medical hub" strategy — presented at the WTO in September 2026 — aiming to grow medical tourism's economic contribution to at least 0.5% of GDP, alongside government-backed innovation programs aimed at professionalizing and upgrading wellness-sector standards and workforce training. That is a genuinely positive, verifiable trend: a government actively trying to formalize and raise standards across a large and fast-growing industry, rather than ignore it.

The caveat is that formal government strategy documents and enforcement actions against unlicensed clinics coexist with an enormous number of wellness businesses that fall outside hospital-grade oversight — spas, drip bars, and aesthetic clinics whose quality and licensing status vary widely and aren't something a traveler can verify from a website alone.

Safety Considerations

Because NAD+ for IV use isn't an approved pharmaceutical product, what patients receive is a compounded preparation — and compounding has produced real, documented safety problems:

• In 2024, the U.S. FDA warned that some compounders were using food-grade NAD+ (intended for oral supplements, not injection) to make sterile IV products, and that food-grade material carries elevated risk of microbial and endotoxin contamination.
• The FDA has received adverse event reports tied to NAD+ injectables — severe chills, violent shaking, vomiting, and fatigue — consistent with endotoxin reactions, some requiring medical treatment.
• In October 2025, the FDA classified a recall of a compounded NAD+ injection as a Class I recall — its most serious category — due to elevated endotoxin levels capable of causing fever, shock, or sepsis.
• In 2026, a patient-safety advocacy group highlighted the death of a New York patient roughly an hour after receiving an IV infusion administered by someone without a license to practice, underscoring risks tied to who is actually performing these infusions and under what oversight.

None of these specific incidents occurred in Thailand, but they illustrate the category-wide risk inherent to any unapproved, compounded IV product: contamination, dosing inconsistency, and variable practitioner oversight — risks that exist wherever such infusions are offered, and that depend heavily on a given facility's licensing status and sourcing practices rather than on national borders.

Bottom Line

NAD+ IV therapy sits at the intersection of a legitimately interesting area of aging biology and a wellness marketing machine that has outrun the evidence. Thailand's wellness and medical tourism sector is large, fast-growing, and increasingly backed by formal government strategy to raise standards — a genuinely positive development worth tracking. But NAD+ IV infusions themselves remain unapproved anywhere as an anti-aging therapy, human evidence for the IV route specifically is essentially absent, and real contamination and licensing incidents tied to compounded NAD+ products have occurred. Anyone considering this treatment, in Thailand or elsewhere, should treat the anti-aging claims with real skepticism and prioritize facility licensing and sourcing transparency over marketing language.